Baseline characteristics and vitreoretinal interface features in patients with vitreomacular traction without macular hole from the MIVI‐TRUST clinical program

• Published in: Acta ophthalmologica (Oxford, England) Vol. 91; no. s252
• Main Authors: KOSHY, Z, LABOUDETTE, A, DUCHATEAU, L, LESCRAUWAET, B
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-08-2013; Wiley Subscription Services, Inc
• Subjects: Drug therapy; Medical research; Ophthalmology
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/j.1755-3768.2013.2416.x

Purpose There is limited published evidence on demographic and vitreoretinal interface (VRI) characteristics of patients with persistent vitreomacular traction (VMT). Establishing characteristics of untreated VMT may contribute to a better understanding of the burden of VMT disease To describe baseline characteristics and VRI features in patients with persistent VMT included in the phase 3 ocriplasmin studies. This analysis reports on VMT patients without macular hole (MH)
Methods Two randomized, double‐masked, placebo‐controlled trials designed to determine efficacy and safety of ocriplasmin for the treatment of VMT comprising 652 patients. Key baseline characteristics included patient demographics (age, gender); eye‐disorder (time since diagnosis, visual acuity (VA) study eye (SE), non‐study eye (NSE), presence of pseudophakia or ERM); VRI features (type of focal VMA, vitreous separation); VFQ‐25 composite score
Results VMT without MH was present in 499 patients (76.5%). Baseline characteristics were: 72.6 years (SD 9.8); 62.7% female. Time since diagnosis was: 268 days (SD 547); VA: SE 66.8 (SD 11.2); NSE 73.5 (SD 16.5). Pseudophakes: 38.7%, concomitant ERM: 46.3 %. The majority of patients presented with focal adhesion ≤1500 microns (69%) and with vitreous adhesions attached at fovea and optic nerve (92%); VFQ‐25 composite score: 78.0 (SD 15.2)
Conclusion Baseline characteristics and vitreoretinal Interface features in patients with vitreomacular traction without macular hole from the MIVI‐TRUST Clinical Program